Key Trends in European Market Access

Recent months have seen a remarkable convergence of initiatives to foster greater European cooperation in market access. On the one hand, the EU has been promoting measures to expedite the launch of new medicines (eg adaptive pathways) and facilitate joint activity in health technology assessment. On the other hand, concerns over the pricing of some new drugs – most notably Gilead’s Sovaldi (sofosbuvir) – have prompted national governments to seek new alliances in order to help control the cost of innovative medicines. Whilst international collaboration in market access has undeniable attractions, it’s important to understand the recent changes thoroughly, especially in terms of the challenges such collaborations are likely to present in practice.

Our latest report provides an in-depth analysis into the recent key developments in the pharmaceutical market access environment and today, we are offering you a complimentary extract of this exclusive report.

This sample extract will provide you with an overview of our latest report ‘Key Trends in European Market Access’ which reviews in-depth the key developments in the pharmaceutical market access environment

Highlights in this report include:

Pros and cons of adaptive pathways for pharmaceutical manufacturers
European initiatives to harmonize health technology assessment (HTA)
Recent national HTA and reimbursement policies in Europe
Italy: Key measures and potential impact of the Health Pact on the pharmaceutical industry
Germany and France: The managed entry environment
Price resistance: Sovaldi case study